RWRevati Wani

Revati Wani

*This is an algorithmically generated author record based on publicly available information.

Revati Wani has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protein redox chemistry: post-translational cysteine modifications that regulate signal transduction and drug pharmacology

    by Revati Wani, Asako Nagata, Brion W. Murray

    The perception of reactive oxygen species (ROS) has evolved over the past decade from agents of cellular damage to secondary messengers which modify signaling proteins in physiology and the disease state (e.g. cancer). New protein targets of specific oxidation are rapidly being identified. One emerging class of redox modification occurs to the thiol side chain of cysteine residues which can produce multiple chemically-distinct alterations to the protein (e.g. sulfenic/sulfinic/sulfonic acid, disulfides). These post-translational modifications (PTM) are shown to affect the protein structure and function. Because redox-sensitive proteins can traffic between subcellular compartments that have different redox environments, cysteine oxidation enables a spatio-temporal control to signaling. Understanding ramifications of these oxidative modifications to the functions of signaling proteins is crucial for understanding cellular regulation as well as for informed-drug discovery process. The effects of EGFR oxidation of Cys797 on inhibitor pharmacology are presented to illustrate the principle. Taken together, cysteine redox PTM can impact both cell biology and drug pharmacology.


  • Open Access

    Broad Phenotypic Changes Associated with Gain of Radiation Resistance in Head and Neck Squamous Cell Cancer

    by Bansal Nidhi, Mims Jade, KuremskyJeffrey G., OlexAmy L., Zhao Weiling, Yin Leimiao, Wani Revati, Qian Jiang, Center Brian, MarrsGlen S., et al.

    Aims: The central issue of resistance to radiation remains a significant challenge in the treatment of cancer despite improvements in treatment modality and emergence of new therapies. To facilitate the identification of molecular factors that elicit protection against ionizing radiation, we developed a matched model of radiation resistance for head and neck squamous cell cancer (HNSCC) and characterized its properties using quantitative mass spectrometry and complementary assays. Results: Functional network analysis of proteomics data identified DNA replication and base excision repair, extracellular matrix-receptor interaction, cell cycle, focal adhesion, and regulation of actin cytoskeleton as significantly up- or downregulated networks in resistant (rSCC-61) HNSCC cells. Upregulated proteins in rSCC-61 included a number of cytokeratins, fatty acid synthase, and antioxidant proteins. In addition, the rSCC-61 cells displayed two unexpected features compared with parental radiation-sensitive SCC-61 cells: (i) rSCC-61 had increased sensitivity to Erlotinib, a small-molecule inhibitor of epidermal growth factor receptor; and (ii) there was evidence of mesenchymal-to-epithelial transition in rSCC-61, confirmed by the expression of protein markers and functional assays ( e.g., Vimentin, migration). Innovation: The matched model of radiation resistance presented here shows that multiple signaling and metabolic pathways converge to produce the rSCC-61 phenotype, and this points to the function of the antioxidant system as a major regulator of resistance to ionizing radiation in rSCC-61, a phenomenon further confirmed by analysis of HNSCC tumor samples. Conclusion: The rSCC-61/SCC-61 model provides the opportunity for future investigations of the redox-regulated mechanisms of response to combined radiation and Erlotinib in a preclinical setting. Antioxid. Redox Signal. 21, 221–236.


  • Open Access

    Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

    by Phillip A. Schwartz, Petr Kuzmic, James Solowiej, Simon Bergqvist, Ben Bolanos, Chau Almaden, Asako Nagata, Kevin Ryan, Junli Feng, Deepak Dalvie, et al.

    Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chemical reactivity in overall potency are not well-understood. To characterize the underlying molecular processes at a microscopic level and determine the appropriate kinetic constants, specialized experimental design and advanced numerical integration of differential equations are developed. Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105–107 M−1s−1), despite their low specific reactivity (kinact ≤ 2.1 × 10−3 s−1), which is compensated for by high binding affinities (Ki < 1 nM). For inhibitors relying on reactivity to achieve potency, noncovalent enzyme–inhibitor complex partitioning between inhibitor dissociation and bond formation is central. Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency. Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions. One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor’s reactive group, which may also contribute to drug resistance. Because covalent inhibitors target a cysteine residue, the effects of its oxidation on enzyme catalysis and inhibitor pharmacology are characterized. Oxidation of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidation (sulfinylation or glutathiolation), and inhibitor architecture. These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors. Significance Covalent kinase inhibition strategies are reemerging, but critical gaps in the understanding of molecular determinants of potency still persist. A kinetic approach is developed to describe the components of overall inhibitor potency (reversible binding and chemical reactivity). Detailed kinetic descriptions of EGFR covalent drugs are provided. Reversible interactions of covalent inhibitors are found to be essential to biochemical and cellular potency. A dynamic linkage between available affinity and necessary reactivity is proposed. Cysteine oxidation is an emerging type of posttranslational modification. Specific oxidation of the EGF receptor cysteine nucleophile causes highly variable effects on inhibitor potency. Two mechanisms of drug resistance are identified (reversible cysteine–inhibitor warhead interactions and specific cysteine oxidation) as well as a rational framework for understanding and designing covalent inhibitors.


  • A simple and effective strategy for labeling cysteine sulfenic acid in proteins by utilization of β-ketoesters as cleavable probes

    by Jiang Qian, Revati Wani, Chananat Klomsiri, Leslie B. Poole, Allen W. Tsang, Cristina M. Furdui

    β-ketoesters are robust probes for labeling sulfenic acid (–SOH) proteins allowing quantitative cleavage of the tag for improved analysis of the labeled peptides by MS.


  • Oxidation of Akt2 kinase promotes cell migration and regulates G1-S transition in the cell cycle

    by Revati Wani, N. Sharmila Bharathi, Jeffrey Field, Allen W. Tsang, Cristina M. Furdui

    Phosphorylation has long been recognized as the key mediator of protein signaling. New modes of signaling regulation are emerging with the development of specific chemical probes and application of high-throughput mass spectrometry technologies. Using biotin-tagged chemical probes for protein oxidation, mass spectrometry and functional assays, our group has recently reported isoform-specific oxidation of Akt2 in response to PDGF signaling. The studies included here investigate the functional consequence of oxidation on Akt2-mediated cell migration and cell cycle. Akt2-KO MEFs transduced with WT and Cys124Ser Akt2 were used as the model system for these studies. The implications of these findings on disease pathology are discussed.


  • Chromate reduction by Burkholderia cepacia MCMB-821,isolated from the pristine habitat of alkaline crater lake

    by Revati Wani, K. M. Kodam, K. R. Gawai, P. K. Dhakephalkar

    The Cr(VI)-reducing bacterial strain MCMB-821 was isolated from the alkaline crater lake of Lonar and was identified as Burkholderia cepacia. MCMB-821 was resistant to 1,000-ppm Cr(VI) and reduced 98% of the 75 ppm Cr(VI) within 36 h at pH 9.0 in the presence of 2% salt and lactose as the electron donor. The chromate-reducing efficiency of MCMB-821 was comparable under both aerobic as well as anaerobic conditions. Electron paramagnetic resonance spectroscopy data suggested that MCMB-821 reduced Cr(VI) to Cr(III) via the formation of transient Cr(V) intermediate. The chromate-reducing ability of MCMB-821 was suppressed in the presence of membrane inhibitors and enhanced in the presence of 2,4-dinitrophenol, suggesting the involvement of electron transport chain in the Cr(VI) bioreduction.